MedCity News
Data breaches at UPMC, Nebraska Medicine affect 250,000+ individuals
Providers are the most common targets for cyber criminals attacking the healthcare industry, and now, two major health systems have added their names to the list of recent data breach victims. The recently divulged information breaches affected 255,000 individuals.
Shares0
Even as the novel coronavirus was raging in the U.S. last year, providers were concurrently fighting a different scourge: hackers.
Several major providers experienced IT incidents in 2020, including the 26-hospital Universal Health Services and University of Vermont Medical Center. Last week, Pittsburgh-based UPMC and Omaha-based Nebraska Medicine announced that they too are on the list.
How healthtech innovation can make the Covid-19 vaccine rollout a success
The vaccine is being delivered to 195 countries with different databases healthcare systems. Healthtech solutions help us bring together data from different healthcare organizations, manufacturing and distributing facilities, and government departments into a centralized location.
Shares0
The vaccine rollout brought about a short-lived sigh of relief. There was immediate doubt around vaccine safety and efficacy. This was then overshadowed by some healthcare workers refusing to take it.
We’re now at a worldwide shortage, while somehow thousands of doses are simultaneously going to waste. Manufacturing and distribution have slowed. Bad handling of vaccines threatens patient safety. In low-income countries, these obstacles are amplified.
Joan Melendez
Joan is the president and CEO of XCelrate UDI has over 25 years of experience with the build and optimization of healthcare applications, specializing in perioperative, anesthesia and trauma workflows. Joan created Xcelrate UDI with the goal of significantly improving patient safety at the point of care by leveraging the power of the UDI for medical devices and tissues.
MedCity News
4 takeaways from 23&Me’s planned SPAC deal
Consumer DNA testing company 23andMe plans to go public through a merger with a special-purpose acquisition company started by Virgin Group. As sales of DNA testing kits wane, how will 23andMe drum up new interest for its business?
Shares0
As sales for DNA testing kits flatten, the companies that make them are faced with a predicament. Revenues are falling as the market became saturated, and more consumers began to wonder about the privacy of their data.
After a bumpy 2020, consumer DNA testing company 23andMe plans to go public through a blank-check deal. The Sunnyvale, Calif.-based business will merge with a special-purpose acquisition company started by Virgin Group in a deal that would value it at $3.5 billion.
Patient volumes were uneven in 2020, and a new report shows volumes will likely remain below pre-pandemic levels in 2021. This indicates challenges for hospitals looking to stabilize their finances but there are some key strategies that can help.